Blood test could catch returning breast cancer early, new drug may stop it
NCT ID NCT07292207
First seen Jan 11, 2026 · Last updated May 09, 2026 · Updated 14 times
Summary
This study looks at whether regular blood tests to find tiny bits of cancer DNA (ctDNA) can catch breast cancer returning early in people with HR+/HER2- breast cancer. If the test turns positive, participants will take a drug called abemaciclib to try to prevent the cancer from coming back. The study involves 30 people and will check how well the drug clears the cancer DNA from the blood and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nagoya City University
Nagoya, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.